Advances in Oligonucleotide Aptamers for NSCLC Targeting

Advances in Oligonucleotide Aptamers for NSCLC Targeting

Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer worldwide, with the highest incidence in developed countries. NSCLC patients often face resistance to currently available therapies, accounting for frequent relapses and poor prognosis. Indeed, despite great recent advancement...

Full description

Bibliographic Details
Main Authors: Deborah Rotoli, Laura Santana-Viera, Maria L. Ibba, Carla L. Esposito, Silvia Catuogno
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:International Journal of Molecular Sciences
Subjects:
NSCLC
SELEX
aptamer
targeted therapy
diagnosis
biomarker discovery
Online Access:https://www.mdpi.com/1422-0067/21/17/6075

Internet

https://www.mdpi.com/1422-0067/21/17/6075

Similar Items